Klin Farmakol Farm. 2020;34(2):70-73 | DOI: 10.36290/far.2020.014
Biosimilar infliximab in pediatrics
- Ústav farmakologie LF UP a FN Olomouc
The first biosimilar for monoclonal antibody introduced into clinical practice in the European Union is infliximab CT-P13. Today, we have sufficiently robust data confirming its efficacy and safety in all indications in the treatment of adult patients. The possibility of the safe switch from the original product to biosimilar has also been proved. Biosimilar infliximab is also approved for the treatment of children with idiopathic inflammatory bowel disease from 6 years of age in whom conventional therapy has failed or is contraindicated. To date, 8 clinical studies have been published, all of which prove the efficacy and safety of biosimilar infliximab in pediatric indications and the possibility of switch from the original product in children. They also show the significant financial savings and improved availability of biologic therapy due to its use.
Keywords: infliximab, biosimilar, children, Crohn's disease, Ulcerative colitis.
Published: July 16, 2020 Show citation
References
- Urbánek K. Specifika regulace biosimilárních léčiv v Evropské unii. In: Tesař V a kol. Biosimilars. Mladá fronta, Praha 2017, pp. 23-33.
- Strojil J. Biosimilars - specifika schvalovacího procesu v EU. Klin Farmakol Farm 2014: 28(1): 14-18.
- K. První biosimilární monoklonální protilátka - infliximab. Klin Farmakol Farm 2014: 28(1): 19-22.
- Gulacsi L, Pentek M, Rencz F et al. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019; 26(2): 259-269.
Go to original source... - Ebada MA, Elmatboly AM, Ali AS, et al. An updated systematic review and meta‑analysis about the safety and efficacy of infliximab biosimilar, CT‑P13, for patients with inflammatory bowel disease. Int J Colorectal, DiS. 2019 Oct; 34(10): 1633-1652. Go to original source...
Go to PubMed... - Sieczkowska J, Jarzębicka D, Banaszkiewicz A, Plocek A, Gawronska A, et al. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. J Crohns Colitis. 2016; 10(2): 127-32. Go to original source...
- Sieczkowska‑Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzębicka D, et al. Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2017; 65(3): 285-288. Go to original source... Go to PubMed...
- Richmond L, Curtis L, Garrick V, Rogers P, Wilson M, Tayler R, Henderson P, Hansen R, Wilson DC, Russell RK. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018; 103(1): 89-91. Go to original source...
- Kang B, Lee Y, Lee K, Choi YO, Choe YH. Long‑term Outcomes After Switching to CT‑P13 in Pediatric‑Onset Inflammatory Bowel Disease: A Single‑Center Prospective Observational Study. Inflamm Bowel, DiS. 2018; 15: 24(3): 607-616. Go to original source...
- Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, et al. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom. Inflammatory Bowel Disease Induction Cohort. J Pediatr Gastroenterol Nutr. 2018; 67(4): 513-519. Go to original source... Go to PubMed...
- Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, et al. Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful. J Pediatr Gastroenterol Nutr. 2018; 67(6): 745-748. Go to original source... Go to PubMed...
- van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, et al. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2019; 41(3): 317-324. Go to original source... Go to PubMed...
- Nikkonen A, Kolho KL. Infliximab and its biosimilar produced similar first‑year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr. 2020 Apr; 109(4): 836-841. Go to original source...